Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Attendees at the first annual Congress held by the European Alliance for Personalised Medicine (EAPM) saw five recipients pick up the inaugural HI-5 awards at the Titanic Belfast last night (Tuesday 28 November).
The term ‘HI-5’ represents the health innovation five, and the awards form an integral part of the Congress, entitled ‘Personalising Your Health: A Global Imperative’.
The four-day event is being held in at the Waterfront venue in Northern Ireland’s capital city.
The first-ever HI-5 wards were given in the following EU-based categories:
The first award went to Regione Lombardia, home of the Italian city of Milan, with the Institut Gustave Roussy in Villejuif, France, landing the EU-based research centre for innovation prize.
The honoured hospital was Vall d´Hebron Institute of Oncology in Barcelona, while pharmaceutical giant Roche won the best company to promote personalised healthcare award.
No individual won the political award - instead, it went to a group of Members of the European Parliament in recognition of their work done in promoting access to personalised medicine.
This award was collected on their behalf by Mary Baker, a past president of the European Brain Council.
Judge Fidelma Macken, a former judge of the Supreme Court of Ireland and European Court of Justice, gave the keynote speech at Titanic Belfast, where delegates had gathered for a gala dinner and the awards ceremony.
The evening was presided over by Denis Horgan and Gordon McVie, executive director and co-chair of EAPM respectively, and the awards were presented by Peter Meeus, Head of Region Europe, Shire, Richard Sullivan, of King’s College London, James N’Dow, Guidelines Office Board at the European Association of Urology, and Mary Baker, a past president of the European Brain Council.
The previous evening had seen two initial awards presented at a welcome reception of r the Congress attendees at Belfast City Hall.
The EAPM SMART Award (Smaller Member states And Regions Together) went to Malta, while the Patient-centric Innovator Award went to AstraZeneca.
The Hon. Christopher Fearne, Minister of Health for Malta, picked up the SMART Award from Peter Meeus, Head of Region Europe at Shire, London, while Ruth March, Senior Vice-President, AstraZeneca’s Precision Medicine and Genomics, picked up her company’s prize from Stephen McMahon, the president of the Irish Patient Association.
Source: EAPM
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.